Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension

被引:9
|
作者
Porres-Aguilar, Mateo [1 ,2 ]
Hoeper, Marius M. [3 ,4 ]
Rivera-Lebron, Belinda N. [5 ]
Heresi, Gustavo A. [6 ]
Mukherjee, Debabrata [7 ]
Tapson, Victor F. [8 ]
机构
[1] Texas Tech Univ, Div Hosp Med, Dept Internal Med, Hlth Sci Ctr, El Paso, TX 79905 USA
[2] Sierra Providence Healthcare & Hosp, Div Hosp Med, Dept Med, El Paso, TX 79902 USA
[3] Hannover Med Sch, Dept Resp Med, Hannover, Germany
[4] German Ctr Lung Res DZL, Hannover, Germany
[5] Univ Pittsburgh Med Ctr UPMC, Div Pulm & Crit Care Med, Pittsburgh, PA USA
[6] Cleveland Clin, Dept Pulm & Crit Care Med, Resp Inst, Cleveland, OH USA
[7] Texas Tech Univ Hlth Sci Ctr El Paso, Dept Med, Div Cardiovasc Dis, El Paso, TX USA
[8] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA USA
关键词
Chronic thromboembolic pulmonary hypertension; Oral anticoagulation; Vitamin K antagonists; Warfarin; Direct oral anticoagulants; Pulmonary embolism; Venous thromboembolism;
D O I
10.1007/s11239-021-02445-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic thromboembolic pulmonary hypertension (CTEPH) represents the later stage consequence of at least one or more unresolved episodes of acute pulmonary embolism; thus, indefinite anticoagulation is strongly recommended by current practice guidelines. Historically, vitamin K antagonists have been widely used in these patients. However, recent data indicate a shift toward direct oral anticoagulants (DOACs), despite lack of data on the safety and efficacy in this patient population. Herein, we briefly discuss the current rationale for oral anticoagulation use in CTEPH, addressing important issues and controversies involved with the use of DOACs, opening a strategy for further clinical research in the field of oral anticoagulation.
引用
收藏
页码:791 / 796
页数:6
相关论文
共 50 条
  • [31] Chronic thromboembolic pulmonary hypertension
    Fedullo, PF
    Kerr, KM
    Auger, WR
    Jamieson, SW
    Kapelanski, DP
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 21 (06) : 563 - 574
  • [32] Chronic thromboembolic pulmonary hypertension
    Michael M. Madani
    Stuart W. Jamieson
    Current Treatment Options in Cardiovascular Medicine, 2000, 2 (2) : 141 - 148
  • [33] Chronic Thromboembolic Pulmonary Hypertension
    Mullin, Christopher J.
    Klinger, James R.
    HEART FAILURE CLINICS, 2018, 14 (03) : 339 - +
  • [34] Chronic Thromboembolic Pulmonary Hypertension
    Jamieson, Stuart
    Pretorius, G. Victor
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2018, 35 (02) : 136 - 142
  • [35] Chronic Thromboembolic Pulmonary Hypertension
    Krittika Teerapuncharoen
    Remzi Bag
    Lung, 2022, 200 : 283 - 299
  • [36] Chronic Thromboembolic Pulmonary Hypertension
    Mahmud, Ehtisham
    Madani, Michael M.
    Kim, Nick H.
    Poch, David
    Ang, Lawrence
    Behnamfar, Omid
    Patel, Mitul P.
    Auger, William R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (21) : 2468 - 2486
  • [37] Chronic thromboembolic pulmonary hypertension
    Piovella, Franco
    D'Armini, Andrea M.
    Barone, Marisa
    Tapson, Victor F.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (08): : 848 - 855
  • [38] Chronic thromboembolic pulmonary hypertension
    Whyte, RI
    Doyle, RL
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 20 (05) : 445 - 452
  • [39] Chronic thromboembolic pulmonary hypertension
    Isabelle, Opitz
    Silvia, Ulrich
    SWISS MEDICAL WEEKLY, 2018, 148
  • [40] Chronic thromboembolic pulmonary hypertension
    Fedullo, PF
    Auger, WR
    Kerr, KM
    Kim, NH
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 24 (03) : 273 - 285